Quantcast

UC Davis Health System

Mark A. Zern, M.D.

Mark A. Zern

Clinical/Research Interests

Mark A. Zern is recognized for his work in liver fibrosis research, gene therapy and the targeting of therapeutics to the liver. He has been an active clinical hepatologist for two decades, and is a former professor of pathology, anatomy and cell biology at Thomas Jefferson University Hospital in Philadelphia. He focus on improving the transplantation process itself and developing novel therapeutic approaches that may make transplantation unnecessary. Although Zern's primary focus is research, he also is a full member of the clinical liver transplantation team. In addition to his bench research, he has edited a book on hepatitis and written monographs on Wilson's disease and alpha 1-antitrypsin deficiency.

Title:

 Professor

Specialty:

 Internal Medicine

Center/Program Affiliation:

 Stem Cell Research Program, Transplant Center

Address:

 Lawrence J. Ellison Ambulatory Care Center
4860 Y St.
Sacramento, CA 95817

Alternate Address

 Lawrence J. Ellison Ambulatory Care Center
4860 Y St.
Sacramento, CA 95817

Phone:

 (916) 734-2111

Education:

 Harvard Medical School
Boston, Massachusetts
M.D. 1975

Harvard University
Cambridge, Massachusetts
A.B. 1969

Internships:

 Harvard Medical School
Boston, Massachusetts
1975-76

Residency:

 Dartmouth College, Mary Hitchcock Hospital
Hanover, New Hampshire
1977-78

Cambridge Hospital
Cambridge, Massachusetts
1976-77

Fellowships:

 Albert Einstein College of Medicine
Bronx, New York
1979-82

Tufts-New England Medical Center
Boston, Massachusetts
1978-79

Board Certifications:

 American Board of Internal Medicine, 1978

Professional Memberships:

 American Association for the Advancement of Science
American Association for the Study of Liver Diseases (AASLD)
American Society of Clinical Investigation
International Association for the Study of the Liver

Select Recent Publications:

Zern MA, Ozaki I, Duan L-X, Pomerantz R, Liu SL, Strayer DS: A novel SV40-based vector successfully transduces and expresses and a 1-antirypsin ribozyme in a human hepatoma-derived cell line. GENE THERAPY 1999;6:114-120

Wu J, Liu P, Zhu J-L, Maddukuri S, Zern MA: Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin. HEPATOLOGY 1998;27:772-778

To see if Mark A. Zern is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.